Câncer de Pele e Renda Familiar: um Estudo Ecológico / Skin Cancer and Family Income: an Ecological Study / Cáncer de Piel y Rendimiento Familiar: un Estudio Ecológico

Introdução: Recentemente, houve crescimento da incidência do câncer de pele. Radiação solar, história familiar, imunossupressão, pele clara e idade constituem fatores de risco da doença. Objetivo: Correlacionar a mortalidade do câncer de pele com variáveis socioeconômicas. Método: Estudo ecológico, utilizando a planilha de dados da incidência de radiação solar do projeto aquecedor solar de baixo custo (ASBC), e indicadores de condições de vida do Censo de 2010. Os dados foram exportados para o SPSS 14.0, para analisar a correlação (coeficiente de correlação de Spearman), e as variáveis foram comparadas. Resultados: Associações estatisticamente significantes ocorreram entre o coeficiente de mortalidade por câncer maligno de pele com a renda familiar média (r=-0,316, p<0,006) indicando que, quanto maior a renda, menor a mortalidade por neoplasia maligna, ocorrendo o mesmo com a proporção de óbitos evitáveis em menores de 4 anos (r=-0,292, p<0,01) e a proporção de mortes evitáveis entre 5 e 74 anos (r=-0,372, p<0,001). A proporção da população ganhando menos de 1/2 salário-mínimo (r=0,232, p<0,05) indica que, quanto maior a proporção populacional com renda inferior a 1/2 salário- -mínimo, maior será a mortalidade por neoplasia maligna, similar à proporção da população ganhando menos de 1/4 de salário-mínimo (r=0,229, p<0,05). Conclusão: Sendo um assunto de saúde pública intimamente relacionado à renda, o câncer de pele ainda carece de ações de prevenção primária e secundária.

Introduction: Recently, there has been an increase in the incidence of skin cancer. Solar radiation, family history, immunosuppression, fair skin and age are risk factors for the disease. Objective: To correlate skin cancer mortality with several socioeconomic variables. Method: An ecological study using the Solar Heating at Affordable (ASBC) Project Solar Radiation Incidence Worksheet, with indicators of living conditions from the 2010 Census. All the collected data were exported to SPSS 14.0, a tool where the correlation (Spearman correlation coefficient) was analyzed and the variables were compared. Results: Statistically significant associations between the mortality coefficient for malignant skin cancer, with mean family income (r=-0.316, p<0.006) were found, indicating that as high the income, lower is the mortality by malignant neoplasm, occurring the same with the proportion of avoidable deaths in children younger than 4 years (r=-0.292, p<0.01) and the proportion of avoidable deaths between 5 and 74 years (r=-0.372, p<0.001). The proportion of the population earning less than ½ minimum wage (r=0.232, p<0.05) indicates that as high the population proportion with income lower than ½ minimum wage, higher will be the mortality by malignant neoplasm, similar to the proportion of the population earning less than » of the minimum wage (r=0.229, p<0.05). Conclusion: Although is a public health issue closely related to income, skin cancer needs initiatives targeted to primary and secondary prevention of the disease.

Introducción: Recientemente, ha habido un aumento en la incidencia de cáncer de piel. La radiación solar, historia familiar, inmunosupresión, piel clara y la edad constituyen los factores de riesgo para esta enfermedad. Objetivo: Correlacionar la mortalidad por cáncer de piel con varias variables socioeconómicas. Método: Se realizo un estudio ecológico usando la base de datos de la incidencia de la radiación solar del proyecto calentador solar de bajo costo (ASBC), adicionando los indicadores del censo de 2010 relativos a las condiciones de vida. Todos los datos recolectados fueron exportados a SPSS 14.0, herramienta que analizó la correlación (coeficiente de correlación de Spearman) y comparar todas las variables de la base de datos. Resultados: Fueran encontró asociaciones estadísticamente significativas entre el coeficiente de mortalidad debido al cáncer maligno de la piel y el ingreso familiar promedio (r=-0,316, p<0,006), lo mismo ocurre con la proporción de muertes prevenibles en niños menores de 4 años de edad (r=-0,292, p<0,01) y la proporción de muertes prevenibles entre 5 y 74 años (r=-0,372, p<0,001). La proporción de la población que gana menos de 1/2 salario mínimo (r=0,232, p<0,05) indica que cuanto mayor es la proporción de la población con ingresos por debajo de 1/2 salario mínimo, mayor es la mortalidad por neoplasia maligna, similar a proporción de la población que gana menos de 1/4 del salario mínimo (r=0,229, p<0,05). Conclusión: A pesar de ser un problema de salud pública y estrechamente relacionado con los ingresos, el cáncer de piel todavía carece de acciones encaminadas a la prevención primaria y secundaria de la enfermedad.

Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020. / Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avançado não cirúrgico e metastático: análise de impacto orçamentário na perspectiva do Sistema Único de Saúde, 2018-2020.

OBJECTIVE: to estimate the incremental budget impact of target therapy for first-line treatment of advanced non-surgical and metastatic melanoma compared to dacarbazine treatment. METHODS: budget impact analysis, from the Brazilian National Health System (SUS) perspective; based on demographic data and incidence estimates, the population over a three-year time horizon (2018-2020) was delimited and the direct medical costs were estimated; the reference scenario was treatment with dacarbazine, and the alternative scenarios were target therapy with vemurafenib, dabrafenib, vemurafenib + cobimetinib and dabrafenib + trametinib; uncertainty assessment was conducted through scenario analysis. RESULTS: the incremental budget impact ranged from R$ 451,867,881.00 to R$ 768,860,968.00, representing 0.70 to 1.53% of total SUS annual outpatient drugs expenditure; in best and worst scenario, results ranged from R$ 289,160,835.00 to R$ 1,107,081,926.00. CONCLUSION: the use of target therapy compared to dacarbazine implies an excessive impact on the budget, this bring unfovorable to its possible incorporation.

Utility of dermoscopy for demarcation of surgical margins in Mohs micrographic surgery.

BACKGROUND: Skin cancer is the most common malignancy and can be treated in various ways. One treatment modality is Mohs micrographic surgery. Due to the increasing incidence of skin cancer in the last decades, there is a need for improvement of the Mohs technique to optimize its effectiveness. OBJECTIVE: The aim of this study was to evaluate the use of dermoscopy to guide demarcation of Mohs micrographic surgery margins and ascertain whether this method can reduce operative time and, therefore, reduce surgical morbidity and cost. METHODS AND MATERIALS: The sample comprised 44 patients who underwent Mohs micrographic surgery, allocated into two groups: the control group and the intervention group. In the latter, surgical margins were guided by dermoscopy. RESULTS: There were no statistically significant differences between the two groups by chi-square analysis (p = 0.399). CONCLUSION: Although outcomes were similar in the two groups, demonstrating that dermoscopy does not help in the demarcation of surgical margins for Mohs micrographic surgery, the study provides a practical proposal for improvement of the Mohs technique.

Utility of dermoscopy for demarcation of surgical margins in Mohs micrographic surgery

BACKGROUND: Skin cancer is the most common malignancy and can be treated in various ways. One treatment modality is Mohs micrographic surgery. Due to the increasing incidence of skin cancer in the last decades, there is a need for improvement of the Mohs technique to optimize its effectiveness. OBJECTIVE: The aim of this study was to evaluate the use of dermoscopy to guide demarcation of Mohs micrographic surgery margins and ascertain whether this method can reduce operative time and, therefore, reduce surgical morbidity and cost. METHODS AND MATERIALS: The sample comprised 44 patients who underwent Mohs micrographic surgery, allocated into two groups: the control group and the intervention group. In the latter, surgical margins were guided by dermoscopy. RESULTS: There were no statistically significant differences between the two groups by chi-square analysis (p = 0.399). CONCLUSION: Although outcomes were similar in the two groups, demonstrating that dermoscopy does not help in the demarcation of surgical margins for Mohs micrographic surgery, the study provides a practical proposal for improvement of the Mohs technique. .

Socioeconomic status as a predictor of melanoma survival in a series of 1083 cases from Brazil: just a marker of health services accessibility?

Melanoma survival is determined by disease-related and patient-related factors; there is a growing body of evidence that other issues may play a role in this disease. In this study, the role of socioeconomic factors in the evolution of melanoma was evaluated. This was a retrospective study with incident cases of melanoma treated in an oncology center in Rio de Janeiro, Brazil, during the period of 1997-2004. The socioeconomic variable of choice was education (9 years or more vs. 8 years or less of school attendance). In this period, there were 1083 patients with primary melanoma of the skin, 58.1% with low school attendance. No difference was found in relation to the year of diagnosis with respect to overall survival. Five-year survival for the entire group was 67.0%. Men had worse survival [hazard ratio (HR) 1.91, 95% confidence interval (CI) 1.54-2.35]; a protective effect was found for whites (HR 0.64, 95% CI 0.49-0.84), higher educational level (HR 0.55, 95% CI 0.44-0.69), and upper limb lesions (HR 0.61, 95% CI 0.38-0.98). A higher risk of death was observed for patients with nodular melanoma (HR 1.96, 95% CI 1.49-2.58), acrolentiginous melanoma (HR 2.68, 95% CI 2.09-3.44), lesions in the soles and palms (HR 1.78, 95% CI 1.22-2.6), and increasing age (HR 1.02 for each year, 95% CI 1.01-1.02). In the multivariate analysis, after controlling for stage, age, sex, ethnicity, and clinical type, education remained a protective factor both for overall survival (HR 0.76, 95% CI 0.61-0.94) and for relapse-free survival (HR 0.76, 95% CI 0.61-0.94). In conclusion, socioeconomic status as measured by educational level represented an important factor related to melanoma clinical evolution in the cohort studied.

An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil.

BACKGROUND: The most common form of cancer in Brazil is non-melanoma skin cancer, which affects approximately 0.06% of the population. There are no public policies for its prevention and the economic impact of its diagnosis has yet to be established. OBJECTIVES: To estimate the costs of the diagnosis and treatment of non-melanoma skin cancer in the state of São Paulo between 2000 and 2007 and to compare them with the costs associated with skin melanoma in the same period. METHODS: The Clinical Practice Guidelines in Oncology (National Comprehensive Cancer Network) was used as a procedure model, adapted to the procedures at the SOBECCan Foundation at the Ribeirão Preto Cancer Hospital in São Paulo. The estimated costs were based on the costs of medical treatment in the public and private sectors in 2007. RESULTS: The mean annual costs of each individual treatment of non-melanoma skin cancer were much lower than those estimated for the treatment of skin melanoma. Nevertheless, when the total costs of the treatment of non-melanoma skin cancer were taken into consideration, it was found that the total cost of the 42,184 cases of this type of cancer in São Paulo within the study period was 14% higher than the costs of the 2,740 cases of skin melanoma registered in the same period within the Brazilian National Health Service (SUS). However, in the private sector, the total cost was approximately 34% less for the treatment of non-melanoma skin cancer compared to melanoma. CONCLUSION: The high number of cases of non-melanoma skin cancer in Brazil, with 114,000 new cases predicted for 2010, 95% of which are diagnosed at early stages, represents a financial burden to the public and private healthcare systems of around R$37 million and R$26 million annually, respectively.

Estimativa do custo do tratamento do câncer de pele tipo não-melanoma no Estado de São Paulo - Brasil / An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil

FUNDAMENTOS: O câncer de maior incidência no Brasil é o de pele não-melanoma, que afeta aproximadamente 0,06 por cento da população. Não existem políticas públicas para sua prevenção e o impacto econômico do seu diagnóstico não tem sido avaliado. OBJETIVOS: Estimar os custos do diagnóstico e tratamento do câncer de pele não-melanoma no Estado de São Paulo entre 2000 a 2007 e compará-los com os do melanoma cutâneo no mesmo período. MÉTODOS: Foi utilizado como modelo de procedimento o projeto diretriz Clinical Practice Guidelines in Oncology, (National Comprehensive Cancer Network), adequado aos procedimentos da Fundação SOBECCan - Hospital do Câncer de Ribeirão Preto - SP. Os custos estimados baseiam-se nos valores do tratamento médico pagos pelos setores público e privado em 2007. RESULTADOS: Os valores médios de custo individual do tratamento anual do câncer de pele não-melanoma são muito mais baixos do que os estimados para o tratamento do melanoma cutâneo. Entretanto, observados os gastos totais no tratamento do câncer de pele não-melanoma, percebe-se que os 42.184 casos deste câncer em São Paulo, no período estudado, fazem com que o custo total do seu tratamento seja 14 por cento superior ao dos 2.740 casos de melanoma cutâneo registrados no mesmo período para o SUS. Porém, para o sistema privado, o gasto total é, aproximadamente, 34 por cento menor para o tratamento do câncer de pele não-melanoma. CONCLUSÃO: O elevado número de casos de câncer de pele não-melanoma no Brasil - com 114 mil novos casos previstos para 2010, sendo 95 por cento diagnosticados em estágios precoces - representa um impacto financeiro ao sistema público e aos sistemas privados de saúde de cerca de R$ 37 milhões e R$ 26 milhões ao ano, respectivamente.

BACKGROUND: The most common form of cancer in Brazil is non-melanoma skin cancer, which affects approximately 0.06 percent of the population. There are no public policies for its prevention and the economic impact of its diagnosis has yet to be established. OBJECTIVES: To estimate the costs of the diagnosis and treatment of non-melanoma skin cancer in the state of São Paulo between 2000 and 2007 and to compare them with the costs associated with skin melanoma in the same period. METHODS: The Clinical Practice Guidelines in Oncology (National Comprehensive Cancer Network) was used as a procedure model, adapted to the procedures at the SOBECCan Foundation at the Ribeirão Preto Cancer Hospital in São Paulo. The estimated costs were based on the costs of medical treatment in the public and private sectors in 2007. RESULTS: The mean annual costs of each individual treatment of non-melanoma skin cancer were much lower than those estimated for the treatment of skin melanoma. Nevertheless, when the total costs of the treatment of non-melanoma skin cancer were taken into consideration, it was found that the total cost of the 42,184 cases of this type of cancer in São Paulo within the study period was 14 percent higher than the costs of the 2,740 cases of skin melanoma registered in the same period within the Brazilian National Health Service (SUS). However, in the private sector, the total cost was approximately 34 percent less for the treatment of non-melanoma skin cancer compared to melanoma. CONCLUSION: The high number of cases of non-melanoma skin cancer in Brazil, with 114,000 new cases predicted for 2010, 95 percent of which are diagnosed at early stages, represents a financial burden to the public and private healthcare systems of around R$37 million and R$26 million annually, respectively.

An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil.

OBJECTIVE: The purpose of this study was to estimate the direct cost of diagnosing and treating melanoma disease in Sao Paulo (Brazil) between the years 2000 and 2007. METHODS: The project Clinical Practice Guidelines in Oncology was used, adapted to the proceedings of SOBECCan Foundation. The estimated costs were based on the values of the medical treatment paid by the Brazilian National Health System (SUS) and private healthcare insurance companies (PHIC) in 2007. RESULTS: The total cost was estimated in R$33,012,725.1 (SUS) and R$76,133,662.8 (PHIC). Stages 0, I and II comprised about 4.2% (SUS) and 1.3% (PHIC) of the total cost; stages III and IV amounted to 95.8% and 98.7% of the total cost, respectively. CONCLUSION: The diagnosis of malignant melanoma in its initial stages reduces treatment costs generating considerable savings of resources for both National Health System and private healthcare insurance companies.

Estimativa do custo do tratamento de câncer de pele tipo melanoma no Estado de São Paulo - Brasil / An estimate of the cost of treating mlanoma disease in the state of Sao Paulo - Brazil

FUNDAMENTOS: O impacto econômico do diagnóstico e do tratamento do melanoma cutâneo não tem sido analisado no Brasil. Uma vez que crescem tanto a incidência do câncer de pele quanto a preocupação com ele, é importante que isto seja avaliado. OBJETIVO: O objetivo deste trabalho foi estimar o custo direto de diagnosticar e tratar em seus diversos estádios o melanoma cutâneo em número de casos ocorridos no Estado de São Paulo, entre 2000 e 2007. MÉTODOS: Como modelo de procedimento, foi utilizado o projeto diretriz (Clinical Practice Guidelines in Oncology), editado pelo National Comprehensive Cancer Network (NCCN) e adequado aos procedimentos da Fundação SobecCan - Hospital do Câncer de Ribeirão Preto - SP. Os custos estimados se baseiam nos valores do tratamento médico pagos pelo setor público (Sistema Único de Saúde - SUS) e pelo setor privado (convênios) em 2007. Houve 2.740 casos diagnosticados e estadiados no Estado de São Paulo no período estudado. RESULTADOS: O custo total de tratamento dos melanomas malignos diagnosticados no estádio inicial, em valores de 2007, foi estimado em R$ 33.012.725,10 para o SUS e R$ 76.133.662,80 para os convênios.Os estádios iniciais 0, I e II da doença compreendem aproximadamente 4,2 por cento (SUS) e 1, 3 por cento (convênios) do custo total; os estádios III e IV consomem 95,8 por cento e 98,7 por cento do custo total, respectivamente. CONCLUSÃO: Os resultados apresentados reforçam o argumento de que o diagnóstico do melanoma cutâneo em seus estádios iniciais reduz os custos de tratamento, gerando considerável economia tanto para o sistema público de saúde (SUS) quanto para o sistema privado (convênios).

OBJECTIVE: The purpose of this study was to estimate the direct cost of diagnosing and treating melanoma disease in Sao Paulo (Brazil) between the years 2000 and 2007. METHODS: The project Clinical Practice Guidelines in Oncology was used, adapted to the proceedings of SOBECCan Foundation. The estimated costs were based on the values of the medical treatment paid by the Brazilian National Health System (SUS) and private healthcare insurance companies (PHIC) in 2007. RESULTS: The total cost was estimated in R$33,012,725.1 (SUS) and R$76,133,662.8 (PHIC). Stages 0, I and II comprised about 4.2 percent (SUS) and 1.3 percent (PHIC) of the total cost; stages III and IV amounted to 95.8 percent and 98.7 percent of the total cost, respectively. CONCLUSION: The diagnosis of malignant melanoma in its initial stages reduces treatment costs generating considerable savings of resources for both National Health System and private healthcare insurance companies.